Potassium%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an essential electrolyte used to treat or prevent hypokalemia. It is available in oral and intravenous (IV) formulations. ## Primary Indications * Treatment and prevention of hypokalemia. * Electrolyte replenishment in various clinical settings. ## Adult Dosing * **Oral:** * For treatment of hypokalemia: Typically 20-60 mEq per day in divided doses. Maximum recommended single dose is 20 mEq. * For prevention of hypokalemia: Typically 20 mEq per day. * Specific dosing depends on severity of deficit and patient response, as determined by serum potassium levels and clinical assessment. Maximum daily oral intake should not exceed 100-120 mEq without close monitoring. * **Intravenous (IV):** * For treatment of hypokalemia: Dosing is highly individualized based on serum potassium levels, rate of correction desired, and patient's clinical status. * Concentrations for IV infusion should not exceed 40 mEq/L in peripheral veins and 80 mEq/L in central veins, unless under exceptional circumstances with continuous cardiac monitoring. * Maximum infusion rate is typically 10-20 mEq/hour in peripheral lines, and up to 40 mEq/hour in central lines with continuous ECG monitoring. Higher rates carry significant risk of cardiac arrest. * In severe hypokalemia or situations requiring rapid correction, higher doses and rates may be used in an ICU setting with continuous cardiac monitoring. ## Pediatric Dosing * **Oral:** * Recommended daily allowance varies by age. For treatment of hypokalemia, doses are typically 1-3 mEq/kg/day divided into 1-4 doses. Maximum single dose usually 20 mEq. * Specific dosing requires careful titration based on serum potassium and clinical assessment. * **Intravenous (IV):** * Dosing is highly individualized. Recommended maintenance is 20-40 mEq per 1000 kcal or 1-2 mEq/kg/day. * For correction of hypokalemia, doses may range from 0.5-1 mEq/kg per dose, infused slowly and with continuous ECG monitoring. * Maximum IV infusion rates and concentrations should follow guidelines for adults, with particular caution in neonates due to limited renal function and cardiac reserve. ## Dose Adjustments * **Renal Impairment:** Dose reduction is necessary. Potassium accumulation can lead to hyperkalemia. Monitor serum potassium closely. * **Hepatic Impairment:** No specific dose adjustment, but monitor electrolytes due to potential fluid shifts. ## Contraindications * Hyperkalemia. * Conditions that may predispose to hyperkalemia (e.g., severe renal impairment, untreated Addison's disease, certain crush injuries, extensive tissue burns). * Known hypersensitivity to potassium chloride. * Esophageal obstruction or delay in gastric emptying (for oral formulations). ## Adverse Effects * **Most Serious:** Hyperkalemia (manifesting as cardiac arrhythmias, peaked T waves on ECG, muscle weakness, paresthesias, paralysis). * **Gastrointestinal (Oral):** Nausea, vomiting, abdominal pain, diarrhea, gastric irritation, ulceration, bleeding. * **Cardiovascular (IV):** Arrhythmias, cardiac arrest (especially with rapid infusion or high doses). * **Other:** Phlebitis (IV), pain at injection site. ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene) and ACE inhibitors/ARBs/DRI:** Increased risk of hyperkalemia. * **NSAIDs:** May reduce the antihypertensive and diuretic effects of potassium and increase the risk of hyperkalemia. * **Digoxin:** Hyperkalemia can increase digoxin toxicity. Hypokalemia can decrease digoxin's effectiveness. * **Beta-blockers:** Can impair potassium transport into cells, potentially leading to increased serum potassium levels and increased risk of hyperkalemia. * **Sodium-glucose cotransporter-2 (SGLT2) inhibitors:** May increase potassium levels. ## Monitoring * Serum potassium levels (frequently, especially with IV administration, dose changes, or in patients with renal impairment). * Renal function (BUN, creatinine). * ECG, particularly during IV infusion or if hyperkalemia is suspected. * Signs and symptoms of hypokalemia and hyperkalemia. * Fluid balance. ## Clinical Pearls * Oral potassium chloride formulations can be irritating to the GI tract; administer with food or fluids to minimize risk. * Dilute IV potassium chloride appropriately before administration. Never administer as a direct IV push. * Continuous cardiac monitoring is essential for patients receiving IV potassium infusion at rates >10-20 mEq/hr or at any rate in patients with known cardiac conduction abnormalities or severe hypokalemia. * "No code blue, no potassium push" is a critical safety mantra. * Consider the underlying cause of hypokalemia for definitive treatment. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols before administering medications. Verify drug and dose with available resources.*